Rabies
Also known as: Hydrophobia
Methodology & AI Transparency ⓘ
Rabies Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Rabies is a deadly animal disease caused by a virus.
- 2 Real-world patient consensus: Synonyms for Rabies (A82.9): Hydrophobia (Migraine & Headache).
- 3 Typical cash cost range: Differential triage of Rabies (A82.9) utilizes preventive threshold assessment in Rabies (A82.9: (>= 4 monthly).
- 4 Top reported side effects / signs: Key Migraine & Headache biomarkers for Rabies (A82.9): RBC Magnesium & in Rabies (A82.9: Riboflavin Status) & Monthly Headache Days in Rabies (A82.9: (MHD)) (< 2 days/month on prevention (A82.9)).
Ask our AI Specialists anything about Rabies
What Is Rabies?
Rabies is a deadly animal disease caused by a virus. It can happen in wild animals, including raccoons, skunks, bats and foxes, or in dogs, cats or farm animals. People get it from the bite of an infected animal. In people, symptoms of rabies include fever, headache and fatigue, then confusion, hallucinations and paralysis. Once the symptoms begin, the disease is usually fatal. A series of shots can prevent rabies in people exposed to the virus. You need to get them right away. If an animal bites you, wash the wound well; then get medical care. To help prevent rabies: Vaccinate your pet.
Pathophysiology, Underlying Causes & Clinical Presentation
Rabies (A82.9) alters migraine & headache homeostasis through calcitonin gene-related peptide in Rabies (A82.9: (CGRP) neuropeptide release); Cross-referenced with NIH MeSH (Rabies), clinical remission targets Monthly Headache Days in Rabies (A82.9: (MHD)) within < 2 days/month on prevention (A82.9).
Common Symptoms & Clinical Signs
- • Vaccinate your pet. Rabies vaccines are available for dogs, cats and farm animals
- • Don't let pets roam
- • Presentation of Rabies (A82.9): moderate-to-severe unilateral throbbing in Rabies (A82.9: or pulsing head)
- • Secondary Rabies clinical sign: heightened sensitivity to in Rabies (A82.9: bright light)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Rabies Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | A82.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Migraine & Headache Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: RBC Magnesium & in Rabies (A82.9: Riboflavin Status) | RBC Mg 5.0 – 6.4 mg/dL (A82.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Monthly Headache Days in Rabies (A82.9: (MHD)) | < 2 days/month on prevention (A82.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: MIDAS Disability Score [Rabies A82.9] | Grade I (0 – 5) (A82.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Rabies
Treatment selection for Rabies depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Rabies)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of ubrogepant based on prior exposure and response to triptans: A post: What a 1,799-Participant Study Found Ubrogepant efficacy and tolerability did not differ for the acute treatment of migraine in participants classified as triptan responders, triptan-insufficient responders, and triptan-naïve based on their historical experience... Headache • 2021-03-15 • Phase III Randomized Trial | N = 1,799 | 96/100 | PMID 33749826 ↗ |
| Can This Approach Help? Inside the Latest Research on CDC Issues Rabies Exposure Indexed from JAMA Network (2026-10-27) by DotMD's 2-hour clinical surveillance pipeline. JAMA Network • 2026-10-27 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 94/100 | PMID JAMA-3770029280 ↗ |
| New Insights on How the body absorbs the medicine and safety comparison of Zamerovimab and: What a 735-Participant Study Found Zamerovimab and Mazorelvimab achieves earlier and higher RVNA titers than HRIG across diverse wound types, with comparable safety. Biologicals : journal of the International Association of Biological Standardization • 2025-11-15 • Phase III Randomized Trial | N = 735 | 93/100 | PMID 40812204 ↗ |
| New Insights on Immunogenicity and Safety of a Purified Vero Rabies Vaccine-Serum Free, Compared: What a 640-Participant Study Found In a simulated PEP setting, PVRV-NG2 + HRIG showed comparable immunogenicity and safety to current standard-of-care vaccines. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2024-06-14 • Phase III Randomized Trial | N = 640 | 93/100 | PMID 38478634 ↗ |
| New Insights on Real-world benefits and safety of SYN023 (Zamerovimab and Mazorelvimab: What a 750-Participant Study Found This study indicates that SYN023, a monoclonal antibody product, may be used as part of rabies post-exposure prophylaxis and provides superior protection sooner after exposure than HRIG. Vaccine • 2025-08-13 • Phase III Randomized Trial | N = 750 | 93/100 | PMID 40479926 ↗ |
Rabies Patient Community & “People Like Me” Threads
Filter Rabies community threads and patient logs by age, biological sex, dosage, and treatment duration.